Study suggests Pfizer-BioNTech vaccine is effective against new Covid-19 strain

  • January 10, 2021 12:05 AM GMT
  • Kunal Sawhney
    CEO Kunal Sawhney
    2212 Posts

    Kunal Sawhney is founder & CEO at Kalkine and is a richly experienced and accomplished financial professional with a wealth of knowledge in the Australian Equities Market. Kunal obtained a Master of Business Administration degree from University of T...

Study suggests Pfizer-BioNTech vaccine is effective against new Covid-19 strain

Summary

  • Scientists have found evidence that proves the Pfizer and BioNTech vaccine, BNT162b2, is effective on the mutated version of coronavirus
  • The Pfizer and BioNTech vaccine was the first one to be rolled out in Britain on 8 December

A recent study has stated that the Pfizer and BioNTech vaccine, BNT162b2, can help in protecting the world against the new variant of the novel coronavirus, which is currently wreaking havoc in the UK.

The two new, highly transmissible variants of the virus that has emerged in Britain and South Africa, has sparked global concern, particularly the E484K mutation found in the South African variant, whether the existing vaccine candidates will be effective. Both the variants share a common mutation -- N501Y.

But scientists have found evidence that the Pfizer and BioNTech vaccine would be effective on the mutated version circulating rapidly in many countries.

(Image source: ©Kalkine Group 2021)

Pfizer had teamed up with researchers from the University of Texas Medical Branch in Galveston for laboratory tests to study if the old vaccine will be effective against the new mutation. A large study was carried out on the blood samples of 20 people who had received the Pfizer and BioNTech vaccine shots. The study disclosed that the antibodies from the vaccine were successful in tackling the virus in lab tests.

On 8 January, BioNTech revealed that the preliminary study showed that its vaccine works against the key mutation in the new strains which is considered to be more contagious than the older strain. The company has also said that tests indicated that BNT162b2-elicited human sera could preserve neutralisation of 15 other mutations of the SARS-CoV-2 virus.

Gary McLean, Professor of Molecular Immunology department of London Metropolitan University, UK, said though the findings are a good piece of news came as good news, the study was not based on the full set of spike mutations of SARS-CoV-2 variant. Therefore, no further conclusions can be made fully at this stage.

The researchers who have carried out the study have also warned that these findings should be viewed cautiously because the paper is yet to be reviewed by the peers.

The study details were shared on the same day when the UK government issued EUA to the third vaccine of Moderna.

Related Read: Covid-19 Vaccine: UK Authorise Moderna Vaccine for Mass Usage

The UK has been seeing a huge increase in the number of Covid-19 infected patients. A total of 68,053 positive cases were reported on 8 January, and the death toll was 1,325. These figures are a cause of concern that have been posing a threat to the already ailing UK economy.

 

 


Disclaimer
The website https://kalkinemedia.com/uk is a service of Kalkine Media Ltd (Kalkine Media), Company Number 12643132. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK